News
Filter Results
Displaying 141–150 of 573
-
Nov 2, 2023
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
Research NewsThe report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Nov 2, 2023
Foundation NewsFirst of its Kind Collaboration Marries Genomics Data with World’s Largest Database of Ophthalmologic Patient Encounters to Improve Accuracy of Clinical Research.
-
Oct 31, 2023
Foundation Fighting Blindness Named Beneficiary for iDox Concert
Foundation NewsSpecial event being held during American Academy of Ophthalmology annual conference in San Francisco, California
-
Oct 25, 2023
Foundation Fighting Blindness and Eone Announce Partnership
Foundation NewsTogether, the Foundation Fighting Blindness and Eone are launching a new limited-edition tactile timepiece watch, the ChangeMaker.
-
Sep 18, 2023
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
Research NewsThe company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
Sep 7, 2023
First Patient Dosed in LCA5 Gene Therapy Clinical Trial Launched by Opus Genetics
Research NewsOpus was established by the RD Fund, the Foundation’s venture philanthropy arm
-
Sep 7, 2023
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
Research NewsThe global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Sep 6, 2023
Therapeutic Targets for Dry AMD: A Foundation Fighting Blindness Webinar for Eye Care Professionals
Foundation NewsThe free, online event will feature a lecture from David Boyer, MD, a Senior Partner at Retina-Vitreous Associates Medical Group and dry AMD expert.
-
Aug 31, 2023
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Aug 28, 2023
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells